dc.contributor.author | Özpak, H.B. | |
dc.contributor.author | Aydın, Cihan | |
dc.contributor.author | Demırkıran, Aykut | |
dc.date.accessioned | 2023-05-06T17:23:33Z | |
dc.date.available | 2023-05-06T17:23:33Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 1308-4488 | |
dc.identifier.uri | https://doi.org/10.5543/tkda.2022.25324 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/12150 | |
dc.description.abstract | OBJECTIVE: We designed a retrospective study to evaluate the performance and outcomes of a novel iopromide-based paclitaxel-coated balloon for the treatment of chronic total occlusion of femoropopliteal arteries. METHODS: Patients with femoropopliteal chronic total occlusion (<100 mm) on angiogram were screened from hospital management system and were included in the study. The width and length of the drug-eluting peripheral balloon was chosen to ensure a vessel/balloon ratio of 1: 1 and exceed the lesion by 10 mm on both ends (based on visual estimation). RESULTS: The proportion of patients with ankle-brachial index improvement was 89.8% (106 of 118). The mean ankle-brachial index was 0.5 (0.4-0.7) at baseline and 0.8 (0.7-0.9) at 12 months (P < 0.001). Changes in the Rutherford category between baseline and 12 months were statistically signi?cant (P < 0.001), with the majority of patients (77.9%, 92/118) having ?1 level improvement. The rate of clinically driven target lesion revasculariza-tion at 12 months was 13.5%(16/118). Overall, the 1-year primary patency rate was 86.4% (102 of 118). The major adverse limb event rate was 9.8% (16/162). Acute limb ischemia was detected in 14 patients, and amputation was performed in 2 patients. CONCLUSION: Our study is a non-randomized clinical study focusing on the use of drug-eluting balloon as a single treatment strategy. There was signi?cant clinical bene?t to patients, as clearly demonstrated by the improvement in ankle-brachial index and the reduction in Rutherford class in the short term, and these results may o?er clear insights on the revascularization strategy outlook of interventionalists. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | NLM (Medline) | en_US |
dc.identifier.doi | 10.5543/tkda.2022.25324 | |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | cardiovascular agent | en_US |
dc.subject | iopromide | en_US |
dc.subject | paclitaxel | en_US |
dc.subject | clinical trial | en_US |
dc.subject | femoral artery | en_US |
dc.subject | human | en_US |
dc.subject | percutaneous transluminal angioplasty | en_US |
dc.subject | peripheral arterial disease | en_US |
dc.subject | popliteal artery | en_US |
dc.subject | procedures | en_US |
dc.subject | retrospective study | en_US |
dc.subject | treatment outcome | en_US |
dc.subject | Angioplasty, Balloon | en_US |
dc.subject | Cardiovascular Agents | en_US |
dc.subject | Femoral Artery | en_US |
dc.subject | Humans | en_US |
dc.subject | Paclitaxel | en_US |
dc.subject | Peripheral Arterial Disease | en_US |
dc.subject | Popliteal Artery | en_US |
dc.subject | Retrospective Studies | en_US |
dc.subject | Treatment Outcome | en_US |
dc.title | Femoro-popliteal Arterlerdeki Kronik Total Oklüzyon Tedavisinde İopromid Bazlı Paklitaksel Kaplı Balonun On İki Aylık Sonuçları | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı | en_US |
dc.identifier.volume | 51 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 112 | en_US |
dc.identifier.endpage | 118 | en_US |
dc.institutionauthor | Aydın, Cihan | |
dc.institutionauthor | Demırkıran, Aykut | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 58146121500 | |
dc.authorscopusid | 55754659100 | |
dc.authorscopusid | 35195470300 | |
dc.identifier.scopus | 2-s2.0-85150311158 | en_US |
dc.identifier.pmid | 36916806 | en_US |